NCT04031677 2026-03-18
STRASS2
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting
Clinical Trials
360 trialsNCT04704661 2026-03-18
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05333458 2026-03-18
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05500391 2026-03-18
SUR-CAN
Centre Oscar Lambret
Phase 2 Recruiting
NCT05691504 2026-03-18
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05907759 2026-03-18
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06211257 2026-03-18
ePPS
Centre Oscar Lambret
Phase NA Recruiting
NCT06422806 2026-03-18
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06498648 2026-03-18
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT06568172 2026-03-18
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT07048249 2026-03-18
Single Arm Romiplostim to Prevent CIT
Children's Hospital Medical Center, Cincinnati
Phase EARLY_PHASE1 Recruiting
NCT07308886 2026-03-18
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07479732 2026-03-18
Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma
Peking University People's Hospital
Phase 1/2 Recruiting
NCT06898970 2026-03-17
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
University of California, San Francisco
Phase 2 Recruiting
NCT06934889 2026-03-17
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT07156565 2026-03-17
ATLAS
Ratio Therapeutics, Inc.
Phase 1 Recruiting
NCT07477457 2026-03-17
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05051059 2026-03-16
QOLSarcoma
Universitaire Ziekenhuizen KU Leuven
Phase NA Recruiting
NCT05950594 2026-03-16
IVIM & OLINK in Sarcoma
University Health Network, Toronto
Phase 2 Recruiting
NCT06865664 2026-03-16
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07194044 2026-03-16
METTSEO
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT07297979 2026-03-16
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Amgen
Phase 1 Recruiting
NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT01804634 2026-03-13
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT02390752 2026-03-13
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT04222413 2026-03-13
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT04902443 2026-03-13
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05735184 2026-03-13
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Phase 1 Recruiting
NCT06843967 2026-03-13
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT07261631 2026-03-13
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Novartis
Phase 1 Recruiting
NCT05269381 2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2 Recruiting
NCT05755113 2026-03-12
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
QBiotics Group Limited
Phase 2 Recruiting
NCT07170644 2026-03-12
A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
SpringWorks Therapeutics, Inc.
Phase 2 Recruiting
NCT05019703 2026-03-11
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06066138 2026-03-11
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06088290 2026-03-11
SaLuDo
PharmaMar
Phase 3 Recruiting
NCT06395103 2026-03-11
MK-9999-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06625190 2026-03-11
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
University of Florida
Phase 1/2 Recruiting
NCT02701153 2026-03-10
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
Jonsson Comprehensive Cancer Center
Phase NA Recruiting
NCT04219202 2026-03-10
Retro-Ion
University Hospital Heidelberg
Phase NA Recruiting
NCT04946357 2026-03-10
EXTREM ION
University Hospital Heidelberg
Phase NA Recruiting
NCT07229313 2026-03-10
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
Phase 1 Recruiting
NCT05957367 2026-03-06
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1/2 Recruiting
NCT03896568 2026-03-05
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05672108 2026-03-05
Phase II Trial of Lung Chemoemobolization
City of Hope Medical Center
Phase 2 Recruiting
NCT07291297 2026-03-05
Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT06760819 2026-03-04
panSOHO
Bayer
Phase 2 Recruiting
NCT06815666 2026-03-04
BAL Fluid Biomarkers in Sarcoma
University Health Network, Toronto
Phase 2 Recruiting
NCT07176689 2026-03-03
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
SpringWorks Therapeutics, Inc.
Phase 4 Recruiting
NCT07249905 2026-03-03
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting